ClinicalTrials.gg
CompletedNCT06050343Updated Sep 22, 2023

Comparative Study of Rinsulin R (GEROPHARM) and Humulin Regular (Eli Lilly) Euglycemic Hyperinsulinemic Clamp Method

An interventional study of Humulin® Regular and Rinsulin® R in Bioequivalence and Therapeutic Equivalency, sponsored by Geropharm. Completed at 1 site in Russian Federation. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-22.

Sponsored by Geropharm · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Feb 2018, registered Aug 2020).
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

Pharmacokinetics and pharmacodynamics of Rinsulin® R, injection solution, 100 IU / ml (GEROPHARM LLC, Russia) and Humulin® Regular, injection solution, 100 IU / ml (Lilly France ", France) using the euglycemic hyperinsulinemic clamp method.

Read the detailed description

A double-blind, randomized, comparative, crossover study of the pharmacokinetics and pharmacodynamics of Rinsulin® R, solution for injection, 100 IU / ml (GEROPHARM LLC, Russia) and Humulin® Regular, solution for injection, 100 IU / ml (Lilly France, France) using euglycemic hyperinsulinemic clamp method on healthy volunteers

02

Conditions studied

  • Bioequivalence
  • Therapeutic Equivalency

Keywords

  • human recombinant insulin
  • euglycemic hyperinsulinemic clamp
03

In context

Lead sponsor

Geropharm is the lead sponsor of 23 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed to participate in the study.
  • Men of the Caucasian race with a verified diagnosis "healthy" according to the data of standard clinical, laboratory and instrumental examination methods.
  • Age 18-50, inclusive.
  • 18.5 - 27 kg / m2.
  • Volunteers who have sexual contact with fertile women should agree to use barrier methods of while participating in the study (unless they have undergone surgical sterilization). Study Participants must also not become a sperm donor within the specified period.
  • Consent to all restrictions imposed during the study.

Exclusion criteria

Exclusion Criteria:

  • Acute inflammatory diseases within 3 weeks from the moment of complete recovery to the stage of screening.
  • Presence of episodes of hypoglycemia in the history of the volunteer
  • Presence in the family history of the closest relatives cases of verified diagnosis of diabetes mellitus of any type.
  • Deviations from the norm of basic vital indicators (heart rate, blood pressure, respiratory rate, body temperature) and from normal values and laboratory values from reference values during screening.
  • Fasting plasma glucose> 6.1 mmol / L at screening.
  • > 6% at the time of screening.
  • Oral glucose tolerance test - blood glucose level ≥7.8 mmol / L (2 hours after glucose loading) during screening.
  • Hard-to-reach veins of the upper extremities, vein thrombosis, history of thrombophlebitis or family history of close relatives, "compromised" veins due to frequent preceding venipuncture.
  • Taking medications, phytopreparations, biologically active additives within 14 days before screening.
  • Significant blood loss 3 months before screening due to, for example, but not limited to the following points: a. donor blood donation; b. extended surgery or trauma leading to significant blood loss.
  • Incomplete recovery from surgery or surgery scheduled while the volunteer is participating in the study.
  • Mental, physical and other reasons interferes with adequately assessing behavior and correctly fulfill the conditions of the research protocol (incl. a history of mental illness).
  • Presence or history (three years before the the study drug) of narcotic, drug and / or substance abuse.
  • Positive test for the content of narcotic drugs in urine during the screening period.
  • Anamnestic information about alcoholism or taking more than 10 units. alcohol per week (1 unit of alcohol is equivalent to 0.5 liters of beer, 200 ml of dry wine or 50 ml of spirits).
  • Positive test for alcohol in breath during screening.
  • Nicotine addiction (regular use of tobacco less than 6 months before screening).
  • Any chronic diseases, incl. but not limited to positive test results for or , , syphilis at the time of screening.
  • Burdened allergological history.
  • Presence of suspicion of an inflammatory disease of the urinary system based on the results of urinalysis during screening.
  • Presence of oncological diseases within 5 years before the screening.
  • History of organ transplantation (except of corneal transplant performed more than 3 months before the first injection of the study drug).
  • Participation in a clinical trial of any drug or experimental medical device within 3 months prior to the first administration of the study drug.
  • Any other condition that, in the reasonable opinion of the research physician, makes it difficult for the volunteer to participate in the study.

History of to heparin, insulin or any of the of the drugs.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Rinsulin® R

    Single subcutaneous administration of Insulin at a dose 0.3 IU / kg

    Drug: Humulin® Regular · Drug: Rinsulin® R

  • Active comparator
    Humulin® Regular

    Single subcutaneous administration of Insulin at a dose 0.3 IU / kg

    Drug: Humulin® Regular · Drug: Rinsulin® R

Interventions

  • DrugHumulin® Regular

    subcutaneous injection at a dose of 0.3 IU / kg

    Also known as: Reference drug

  • DrugRinsulin® R

    subcutaneous injection at a dose of 0.3 IU / kg

    Also known as: Test Drug

06

What researchers measure

Primary outcomes

  1. Смах

    Drug Observed Maximum Plasma Concentration

    Time frame: -60 minutes, -30 minutes, 0, every 15 minutes till 4 hours and then every 30 minutes till 10 hours

  2. AUC 0-10

    Total area under the curve "drug concentration - time" in the time interval from 0 to 10 h

    Time frame: -60 minutes, -30 minutes, 0, every 15 minutes till 4 hours and then every 30 minutes till 10 hours

  3. AUC GIR 0-12

    Total area under the curve "glucose infusion rate - time" in the time interval from 0 to 12 h

    Time frame: - 120 minutes, -90 minutes, -60 minutes, -30 minutes, 0, every 5 minutes till 8 hours, then every 10 minutes till 10 hours and then every 30 minutes till 12 hours

  4. GIRmax

    Time to reach maximum glucose infusion rate

    Time frame: -120 minutes, -90 minutes, -60 minutes, -30 minutes, 0, every 5 minutes till 8 hours, then every 10 minutes till 10 hours and then every 30 minutes till 12 hours

Secondary outcomes

  1. tGIRmax

    Time to reach maximum glucose infusion rate

    Time frame: -120 minutes, -90 minutes, -60 minutes, -30 minutes, 0, every 5 minutes till 8 hours, then every 10 minutes till 10 hours and then every 30 minutes till 12 hours

  2. AUC 0-2

    Total area under the curve "drug concentration - time" in the time interval from 0 to 2 h

    Time frame: -60 minutes, -30 minutes, 0, every 15 minutes till 4 hours and then every 30 minutes till 10 hours

  3. AUC 0-4

    Total area under the curve "drug concentration - time" in the time interval from 0 to 4 h

    Time frame: -60 minutes, -30 minutes, 0, every 15 minutes till 4 hours and then every 30 minutes till 10 hours

  4. AUC 0-6

    Total area under the curve "drug concentration - time" in the time interval from 0 to 6 h

    Time frame: -60 minutes, -30 minutes, 0, every 15 minutes till 4 hours and then every 30 minutes till 10 hours

  5. Tmax

    Time to reach test drug Maximum Plasma Concentration

    Time frame: -60 minutes, -30 minutes, 0, every 15 minutes till 4 hours and then every 30 minutes till 10 hours

  6. T1/2

    Half-life of a test drug

    Time frame: -60 minutes, -30 minutes, 0, every 15 minutes till 4 hours and then every 30 minutes till 10 hours

  7. tGIRlag

    Time between the drug administration and the onset of action

    Time frame: -120 minutes, -90 minutes, -60 minutes, -30 minutes, 0, every 5 minutes till 8 hours, then every 10 minutes till 10 hours and then every 30 minutes till 12 hours

  8. AUC GIR 0-2

    Total area under the curve "glucose infusion rate - time" in the time interval from 0 to 2 h

    Time frame: -120 minutes, -90 minutes, -60 minutes, -30 minutes, 0, every 5 minutes till 8 hours, then every 10 minutes till 10 hours and then every 30 minutes till 12 hours

  9. AUC GIR 0-4

    Total area under the curve "glucose infusion rate - time" in the time interval from 0 to 4 h

    Time frame: - 120 minutes, -90 minutes, -60 minutes, -30 minutes, 0, every 5 minutes till 8 hours, then every 10 minutes till 10 hours and then every 30 minutes till 12 hours

  10. AUC GIR 0-6

    Total area under the curve "glucose infusion rate - time" in the time interval from 0 to 6 h

    Time frame: -120 minutes, -90 minutes, -60 minutes, -30 minutes, 0, every 5 minutes till 8 hours, then every 10 minutes till 10 hours and then every 30 minutes till 12 hours

07

Study locations

1 site
  • "National Medical Research Center of Endocrinology" of the Ministry of Health of the Russian Federation
    Moscow, 117036, Russian Federation
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06050343
Lead sponsor
Geropharm
Responsible party
Sponsor
First posted
Sep 22, 2023
Start date
Feb 19, 2018
Primary completion
May 4, 2018
Completion
May 4, 2018
Last update
Sep 22, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion